N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Comparing Perclose to Statseal With Perclose in Transcatheter Aortic Valve Replacement Arteriotomy Closure
Arterial Occlusion · Cardiovascular Diseases · Hematoma
Primary: Time to Hemostasis — 5.11; 4.3 minutes
N/A N=75 Safety and Performance Study of Large Hole Vascular Closure Device FIV
Percutaneous CFA Arteriotomy Closure
Primary: Major Vascular Complications [Safety] — 0 Participants — p=<.0001
N/A N=434 VAscular Closure for Cardiac Ablation Registry (VACCAR)
Atrial Fibrillation
Primary: Hemostasis — 9; 20; 7 minutes
N/A N=106 Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
Atrial Fibrillation · Atrial Flutter · Heart Block
Primary: Time to Achieve Hemostasis — 7; 11 Minutes
N/A N=12 Safety and Performance Study of Large Hole Vascular Closure Device
Percutaneous Closure of Arteriotomy in Common Femoral Artery
Primary: Major Vascular Complications Directly Related to Device — 0 percentage of participants
N/A N=147 Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
Vascular Closure
Primary: Freedom From Major Complications — 83 Participants
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
N/A N=207 Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)
Cardiac Disease · Coronary Artery Disease
Primary: The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure. — 1…
N/A N=263 MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study
Femoral Arteriotomy Closure
Primary: Time to Hemostasis — 65.4 seconds
Phase 4 N=240 AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: First Occurrence of Access Site Related Ischemic or Bleeding Complication — 16; 15 Participants
Phase 3 N=488 Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device
Angioplasty, Transluminal, Percutaneous Coronary · Coronary Arteriosclerosis · Peripheral Arteriosclerosis
Primary: Time to Hemostasis (TTH) — 4.68; 4.38; 20.05 Minutes — p=<0.0001
N/A N=75 Caring for the Radial Artery Post-angiogram
Transradial Angiogram
Primary: Bleeding Requiring Intervention After Initial Hemostasis Achieved — 2; 6; 3 participants — p=0.25
N/A N=326 ClosureFAST - Radiofrequency Great Saphenous Vein Treatment
Venous Reflux
Primary: Percentage of Limbs Without Vein Occlusion — 97.6 percentage of limbs
N/A N=351 A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System
Diagnostic Catheterization Access Through a 5F or 6F Femoral Artery Introducer
Primary: Observation of Any Site Related Complications Recorded as Either Major or Minor Adverse Events.
N/A N=36 Perclose Multi-Access Duplex Ultrasound (DUS) Study
Arrhythmia
Primary: Number of Subjects With Major Vascular Complications by DUS Detection at Discharge — 0; 0; 0; 0 Participants
N/A N=92 This Study Will Evaluate the Safety and Potential Complications of Dual ProGlide vs Single ProGlide and Angioseal for Common Femoral Arteriotomy Closure Following Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement · Closure Technique
Primary: Number of Participants With Main Access-related Bleeding and Vascular Complications — 47; 42 Participants
N/A N=168 AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)
Surgical Wound
Primary: Number of Participants With Overall Procedure Success - Effectiveness — 168 Participants
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 2 N=147 Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)
Coronary Artery Chronic Total Occlusion
Primary: Technical Success — 77 percentage of CTOs
N/A N=980 Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
Cryptogenic Stroke
Primary: Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization — 9; 16 Participants — p=0.08
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
N/A N=160 Novel Angioplasty Using Coronary Accessor
Patency of the Radial Artery
Primary: Number of Patients With Radial Artery Occlusion — 3; 0 Participants
N/A N=47 X-Seal EU Post-Market Clinical Follow-Up Protocol
Femoral Arteriotomy Closure
Primary: Major Complications — 0; 0 Participants
N/A N=664 GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
Stroke · Transient Ischemic Attack
Primary: Number of Subjects With Freedom From Recurrent Ischemic Stroke (Primary Outcome #1) — 6; 12 Participants — p=0.001
N/A N=150 Chronic Total Occlusion Percutaneous Coronary Intervention Study
Chronic Total Occlusion · Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery
Primary: Number of Participants With Procedure Success — 121 Participants
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=220 The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System
Surgical Wound
Primary: Time to Hemostasis — 1.78 minutes
N/A N=50 Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device
Femoral Arteriotomy Closure
Primary: Number of Participants With Major Complications — 3 Participants
N/A N=88 Chronic Total Occlusion Crossing With the Wildcat Catheter
Peripheral Arterial Disease
Primary: Major Adverse Events — 4 participants